This page shows the publications co-authored by David Avigan and Rebecca Karp.
Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. Curr Hematol Malig Rep. 2015 Dec; 10(4):395-404.
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. J Cell Mol Med. 2018 Aug; 22(8):3887-3898.
DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma. J Immunother. 2017 Nov/Dec; 40(9):315-322.
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Mol Cancer Ther. 2017 10; 16(10):2304-2314.
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017 Mar 30; 129(13):1791-1801.
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938.
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 06 21; 131(25):2836-2845.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.